Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4

BACKGROUND: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. However, the efficacy of FOLFOX4 for HCC patients is st...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Asian Pac J Cancer Prev
Главные авторы: Qin, Shukui, Zhang, Xinji, Guo, Wei, Feng, Jian, Zhang, Tianyi, Men, Lichuang, He, Jia
Формат: Artigo
Язык:Inglês
Опубликовано: West Asia Organization for Cancer Prevention 2017
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5555527/
https://ncbi.nlm.nih.gov/pubmed/28610406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2017.18.5.1225
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы